Related Experiment Video

Updated: May 29, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease

Michael Lian1, Tim D Hewitson, Belinda Wigg

  • 1Department of Nephrology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|September 13, 2011
PubMed

Insights

Eplerenone (EPL) treatment reduced kidney damage in a diabetic rat model. This mineralocorticoid receptor blocker mitigated albuminuria and collagen buildup, suggesting a renoprotective effect in diabetic renal disease.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic renal disease is characterized by collagen accumulation and renal fibrosis.
  • Aldosterone antagonism has shown promise in slowing the progression of renal fibrosis.
  • Mineralocorticoid receptor blockers represent a potential therapeutic strategy for diabetic nephropathy.

Purpose of the Study:

  • To investigate the renoprotective effects of eplerenone (EPL), a mineralocorticoid receptor blocker, in an accelerated model of Type I diabetes.
  • To assess the impact of EPL on functional and structural parameters of diabetic renal disease in streptozotocin (STZ)-treated spontaneously hypertensive rats (SHR).

Main Methods:

  • STZ-induced diabetic SHR were randomly assigned to receive EPL (100 mg/kg/day) or no treatment for 16 weeks.
  • Functional parameters (e.g., albuminuria) and structural parameters (e.g., kidney weight/body weight ratio, glomerular size, collagen IV deposition) were evaluated.
  • Transforming growth factor beta 1 (TGFβ1) expression and macrophage infiltration were assessed.

Main Results:

  • EPL treatment significantly ameliorated progressive albuminuria from Week 12 onwards in STZ-SHRs.
  • EPL reduced elevated kidney weight/body weight ratio, glomerular volume, TGFβ1 expression, and glomerular collagen IV staining.
  • While EPL improved structural and functional markers, it did not alter glomerular macrophage infiltration.

Conclusions:

  • Eplerenone demonstrates a significant renoprotective role in this accelerated model of diabetic renal disease.
  • The findings suggest that mineralocorticoid receptor blockade with EPL can mitigate key pathological features of diabetic nephropathy.
  • EPL's ability to reduce fibrosis and albuminuria highlights its therapeutic potential for managing diabetic kidney disease.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...